{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T04:32:06Z","timestamp":1741667526588,"version":"3.38.0"},"reference-count":69,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"},{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Womens Health (Lond Engl)"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:p> Overactive bladder is a debilitating disorder affecting 16.5% of adults and increasing in prevalence with age. Symptoms, including urgency, urge incontinence and frequency can result from detrusor overactivity with contraction of the bladder mediated primarily by activation of muscarinic M<jats:sub>3<\/jats:sub> receptors. Antimuscarinic agents are therefore an important approach to treating overactive bladder, but a lack of M<jats:sub>3<\/jats:sub> receptor subtype selectivity with these agents can generate a range of side effects that limits their effectiveness. This review describes an alternative approach to treating overactive bladder using the selective muscarinic M<jats:sub>3<\/jats:sub> receptor antagonist darifenacin. The M<jats:sub>3<\/jats:sub> receptor selectivity of darifenacin improves the symptoms of overactive bladder while reducing the potential for deleterious effects of non-M<jats:sub>3<\/jats:sub> muscarinic receptor antagonism in the brain or heart. The pharmacology and pharmacokinetics of darifenacin are summarized, and the its clinical efficacy and demonstrated safety profile are described. <\/jats:p>","DOI":"10.2217\/17455057.1.3.331","type":"journal-article","created":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T11:16:38Z","timestamp":1133435798000},"page":"331-343","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Darifenacin for the Treatment of Overactive Bladder"],"prefix":"10.1177","volume":"1","author":[{"given":"Fran\u00e7ois","family":"Haab","sequence":"first","affiliation":[{"name":"D\u00e9partment d'Urologie, H\u01d2pital Tenon, 4 Rue de la Chine, 75020 Paris, France, Tel.: +33 156 016 495; Fax: +33 156 017 306;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,11,1]]},"reference":[{"key":"bibr0101-17455057.1.3.331","unstructured":"Papers of special note have been highlighted as either of interest (\u2022) or of considerable interest (\u2022\u2022) to readers."},{"key":"bibr1-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"bibr010001-17455057.1.3.331","unstructured":"Internationally accepted definitions of the symptoms, signs, urodynamics observations and conditions associated with urodynamics studies and lower urinary tract dysfunction, including overactive bladder (OAB)."},{"key":"bibr2-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"bibr010002-17455057.1.3.331","unstructured":"Summary of the characteristics, symptoms and prevalence of OAB in Europe."},{"key":"bibr3-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-002-0301-4"},{"key":"bibr010003-17455057.1.3.331","unstructured":"Summary of the prevalence and burden of OAB in the USA."},{"key":"bibr4-17455057.1.3.331","first-page":"S580","volume":"6","author":"Abrams P","year":"2000","journal-title":"Am. J. Manag. Care"},{"key":"bibr010004-17455057.1.3.331","unstructured":"Detailed review of the impairment in quality of life for patients with OAB"},{"key":"bibr5-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.10.037"},{"key":"bibr6-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704781"},{"key":"bibr7-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00622-7"},{"key":"bibr010005-17455057.1.3.331","unstructured":"Review of the rationale for using antimuscarinic agents for OAB and the potential effects of these drugs in nonbladder tissue."},{"key":"bibr8-17455057.1.3.331","doi-asserted-by":"crossref","unstructured":"Andersson KE: Potential benefits of muscarinic M3 receptor selectivity. Eur. Urol. Suppl. 1 23\u201328 (2002).","DOI":"10.1016\/S1569-9056(02)00045-3"},{"key":"bibr010006-17455057.1.3.331","unstructured":"Detailed review of the role of muscarinic receptors in the body and the potential effects of agents with muscarinic M3 receptor selectivity."},{"key":"bibr9-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1997.tb12054.x"},{"key":"bibr10-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200118070-00007"},{"key":"bibr11-17455057.1.3.331","unstructured":"Napier C, Gupta P: Darifenacin is selective for the human recombinant M3 receptor subtype. Proceedings of the Annual Meeting of the International Continence Society. Heidelberg, Germany (2002) (Abstract 445)."},{"key":"bibr010007-17455057.1.3.331","unstructured":"Single study comparing the affinity of different OAB treatments at all five muscarinic receptor subtypes."},{"key":"bibr12-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1159\/000073665"},{"key":"bibr13-17455057.1.3.331","first-page":"462","volume":"20","author":"Yoshida M","year":"2001","journal-title":"Neurourol. Urodyn."},{"key":"bibr14-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-002-0554-x"},{"key":"bibr15-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(03)80464-5"},{"key":"bibr16-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(02)80508-5"},{"key":"bibr17-17455057.1.3.331","volume":"120","author":"Williamson IJ","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"bibr18-17455057.1.3.331","volume":"117","author":"Davies CL","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"bibr19-17455057.1.3.331","doi-asserted-by":"crossref","unstructured":"Napier C, Laskey P, Gupta P, Clarke NP: Competitive and reversible interaction of darifenacin with human recombinant M3 receptors. Eur. Urol. Suppl. 2 (2003) (Abstract 780).","DOI":"10.1016\/S1569-9056(03)80782-0"},{"key":"bibr20-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.067140"},{"key":"bibr21-17455057.1.3.331","unstructured":"Skerjanec A, Devineni D: Affinity of darifenacin for the P-glycoprotein efflux pump: a mechanism contributing to the CNS sparing profile? Presented at the British Pharmacological Society Winter Meeting. Liverpool, UK. December 14\u201316 (2004)."},{"key":"bibr22-17455057.1.3.331","unstructured":"Darifenacin, Enablex\u00ae, Prescribing Information. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA (2004)."},{"key":"bibr23-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01967.x"},{"key":"bibr24-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1080\/004982598239768"},{"key":"bibr25-17455057.1.3.331","first-page":"89","volume":"89","author":"Nichols DJ","year":"2001","journal-title":"Pharmacol. Toxicol."},{"key":"bibr26-17455057.1.3.331","unstructured":"Devineni D, Skerjanec A, Greig G, Woodworth TG: Pharmacokinetics of darifenacin, an M3 selective receptor antagonist: effects of renal or hepatic impairment. Proceedings of the British Pharmacological Society Winter Meeting. Liverpool, UK. December 14\u201316 (2004)."},{"key":"bibr27-17455057.1.3.331","first-page":"S32","volume":"12","author":"Salvatore S","year":"2001","journal-title":"Int. Urogynecol. J. Pelvic Floor Dysfunct."},{"key":"bibr28-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.01.008"},{"key":"bibr010008-17455057.1.3.331","unstructured":"Detailed report of a Phase III fixed-dose trial of darifenacin (primary publication)."},{"key":"bibr29-17455057.1.3.331","doi-asserted-by":"crossref","unstructured":"Hill S, Khullar V, Wyndaele J-J, Lheritier K, on behalf of the Darifenacin Study Group: Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int. Urogynecol. J. Pelvic Floor Dysfunct. July 6 (2005) (Epub ahead of print).","DOI":"10.1007\/s00192-005-1340-3"},{"key":"bibr010009-17455057.1.3.331","unstructured":"Detailed report of a Phase III fixed-dose trial assessing three doses of darifenacin (primary publication)."},{"key":"bibr30-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05343.x"},{"key":"bibr0100010-17455057.1.3.331","unstructured":"Detailed report of the Phase III flexible-dose trial of darifenacin (primary publication)."},{"key":"bibr31-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05454.x"},{"key":"bibr0100011-17455057.1.3.331","unstructured":"Detailed report of the pooled analysis from the Phase III fixed-dose trials of darifenacin."},{"key":"bibr32-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.83.s2.3.x"},{"key":"bibr33-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2003.04168.x"},{"key":"bibr34-17455057.1.3.331","unstructured":"Khullar V, Hill S, Steel M, Quebe-Fehling E: Darifenacin in the treatment of overactive bladder: dose-response effects on urinary symptoms in Phase III trials. Proceedings of the Annual Meeting of the International Continence Society. Montreal, Canada, 31 August\u20132 September (2005 (Abstract 145)."},{"key":"bibr35-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.018"},{"key":"bibr36-17455057.1.3.331","doi-asserted-by":"crossref","unstructured":"Zinner N, Tuttle J, Marks L: Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J. Urol. (2005) (Epub ahead of print).","DOI":"10.1007\/s00345-005-0507-3"},{"key":"bibr37-17455057.1.3.331","unstructured":"Foote J, Elhilali M: A multicenter, randomized, double-blind study of darifenacin versus tolterodine in the treatment of overactive bladder (OAB). Poster presented at Annual Meeting of the British Geriatrics Society. Harrogate, UK. October 6\u20138 (2004)."},{"key":"bibr38-17455057.1.3.331","first-page":"S88","volume":"105","author":"Romanzi LJ","year":"2005","journal-title":"Obstet. Gynecol."},{"key":"bibr0100012-17455057.1.3.331","unstructured":"Preliminary report of the Phase III trial comparing darifenacin and tolterodine."},{"key":"bibr39-17455057.1.3.331","unstructured":"Steers W, Dwyer P, Gittelman M, Lheritier K, Kawakami F: Efficacy of darifenacin in a 2-year long-term extension study in patients with overactive bladder. Proceedings of the Annual Meeting of the International Continence Society. Montreal, Canada, 31 August-2 September (2005) (Abstract 149)."},{"key":"bibr40-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01795-8"},{"key":"bibr41-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.05.009"},{"key":"bibr42-17455057.1.3.331","first-page":"MP18","volume":"18","author":"Kerr L","year":"2004","journal-title":"J. Endourol."},{"key":"bibr43-17455057.1.3.331","volume":"94","author":"Chapple C","year":"2004","journal-title":"BJU Int."},{"key":"bibr44-17455057.1.3.331","unstructured":"Reese P, Niecko T, Huels J, Kelleher C: Darifenacin provides clinically meaningful quality of life improvements in patients with overactive bladder assessed by minimal important difference (MID) analysis. Proceedings of the Annual Meeting of the International Continence Society Montreal, Canada. 31 August\u20132 September (2005) (Abstract 326)."},{"key":"bibr45-17455057.1.3.331","first-page":"S101","volume":"16","author":"Abrams P","year":"2005","journal-title":"Int. Urogynecol. J. Pelvic Floor Dysfunct."},{"key":"bibr46-17455057.1.3.331","first-page":"23","volume":"14","author":"Steel M","year":"2004","journal-title":"Prog. Urol."},{"key":"bibr47-17455057.1.3.331","volume":"94","author":"Glavind K","year":"2004","journal-title":"BJU Int."},{"key":"bibr48-17455057.1.3.331","first-page":"S101","volume":"16","author":"Thomas S","year":"2005","journal-title":"Int. Urogynecol. J. Pelvic Floor Dysfunct."},{"key":"bibr49-17455057.1.3.331","first-page":"351","volume-title":"Rome II. The Functional Gastrointestinal Disorders","author":"Thompson WG","year":"2000","edition":"2"},{"key":"bibr50-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.5.771"},{"key":"bibr51-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7119.1363"},{"key":"bibr52-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05745.x"},{"key":"bibr53-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000148963.21096.5d"},{"key":"bibr54-17455057.1.3.331","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005279010"},{"key":"bibr55-17455057.1.3.331","unstructured":"Steers W, Dwyer P, Gittelman M, Lheritier K, Kawakama FT: Long-term tolerability and safety of darifenacin demonstrated in a 2-year extension study in patients with overactive bladder. Proceedings of the Annual Meeting of the International Continence Society Montreal, Canada, 31 August\u2013September (2005) (Abstract 141)."},{"key":"bibr101-17455057.1.3.331","unstructured":"European Medicines Agency (EMEA) Emselex European Public Assessment Report (EPAR): scientific discussion. www.emea.eu.int\/humandocs\/Humans\/EPAR\/emselex\/emselex.htm (Accessed October 2005)"}],"container-title":["Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/17455057.1.3.331","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.2217\/17455057.1.3.331","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.2217\/17455057.1.3.331","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T19:56:20Z","timestamp":1741636580000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.2217\/17455057.1.3.331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.2217\/17455057.1.3.331"],"URL":"https:\/\/doi.org\/10.2217\/17455057.1.3.331","relation":{},"ISSN":["1745-5057","1745-5065"],"issn-type":[{"type":"print","value":"1745-5057"},{"type":"electronic","value":"1745-5065"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}